CVS HEALTH Corp (CVS): what the price requires

The current priced-in claim for CVS HEALTH Corp (CVS) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/CVS

Headline

FieldValue
TickerCVS
CompanyCVS HEALTH Corp
Current price$106.29/sh
CompositionPharmacy 57% / Front Store 5% / Premiums 34% / Net investment income 1% / Other 4%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed3.1%
Operating margin (mid-cycle)5.8%
Margin compression implied-2.7pp
Trailing margin (depressed year)1.8%
Multiple paid9x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.2% sits below it).

How unusual the bet is: within-range

ReferenceValue
vs own history-0.21σ
cohort percentile (of 210 peers)13
implied end-window share1%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset4.46x3expensive
Earnings9.92x3expensive
Relative1.67x3expensive
Growth1.03x2expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.2%); the inversion above states its own rate.

Per-Model Detail (n=11)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
DCF Exit MultipleGrowth$129.780.82xyesExit EV/EBITDA: 17.2x / 19.2x / 21.2x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$49.802.13xyesP/E 44x (blended: static sector reference 20x + trailing (TTM) 139x), scenarios: 36.8x / 44.0x / 51.2x (bear / base = reference held flat / bull), EV/EBITDA 14x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$8.2512.88xyesBV/sh $60.56, ROE (TTM) 1.3%, ke 9.3%
Two-Stage Excess ReturnAsset$4.4323.99xyes5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market CapGrowth$85.241.25xyesRev $407.9B, growth 8% (input: historical growth; tapered), Terminal P/S: 0.3x / 0.3x / 0.4x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$51.402.07xyesNormalized EBIT (5y avg op income, one-time charges added back) $11.08B × (1−25%) / WACC 6.2% → EPV (no growth)
Residual IncomeAsset$3.1733.53xyesBV $60.56 + 5yr PV of (ROE (TTM) 1.3% − Kₑ 9.3%) × BV; BV grows 0.8%/yr (excluded from median)
Graham NumberAsset$31.803.34xyes√(22.5 × EPS $0.74 × BVPS $60.56) — Graham's conservative floor
EV/EBITDA RelativeRelative$63.521.67xyesEBITDA $10.53B × sector EV/EBITDA 14.0x
FCF YieldEarnings$10.729.92xyesFCF $7394.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$5.0221.17xyesSBC-adj FCF $6.72B (FCF $7.39B − SBC $0.68B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$0.62171.44xyesEPS $0.74 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$23.844.46xyesBV $60.56 × (ROIC 2.4% / WACC 6.2%)
P/Sales SectorRelative$478.390.22xyesRevenue $407.90B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$8.0213.25xyesEPS $0.74 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$54.1b
Net debt / NOPAT (after-tax)3.10x
Net debt / operating income (pre-tax)2.33x
Interest coverage7.5x
Share count CAGR (buyback)-0.9%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 5.8%); the trailing year was depressed.

Bullet Takeaways

CVS is a mature, low-margin healthcare conglomerate, so its 1.5% operating margin is a feature of the volume model, not a flaw. At about 9x normalized operating income the price sits below what even a 5%-a-year decline in operating profit would warrant.

The Q1 2026 turnaround was real: revenue topped $100 billion, adjusted EPS rose over 14% to $2.57, the Aetna medical benefit ratio improved to 84.6%, and management raised full-year adjusted EPS guidance to $7.30 to $7.50.

The balance sheet carries the cost of empire-building: about $54 billion of net debt, roughly 2.3x operating income, with interest covered 7.7 times, alongside a dividend yielding around 3.5%.

Bull Case

Start by framing the stage, because CVS is a mature, integrated healthcare company and its numbers have to be read that way. The composition is telling: pharmacy is 57% of revenue, insurance premiums 34%, with the front store and other services filling out the rest. This is a high-volume, low-margin business by design, so the 1.5% operating margin that looks alarming in isolation is normal for a company that moves over $400 billion of revenue through pharmacies, a pharmacy-benefit manager, and the Aetna insurer. The right lens is not the margin; it is whether the integrated model, which combines insurance, the Caremark PBM, retail pharmacy, and care delivery, can convert that volume into durable, growing profit. The first quarter said yes.

The turnaround is showing up in the results that matter most. Q1 2026 revenue exceeded $100 billion, up over 6%, adjusted operating income rose over 12%, and adjusted EPS climbed over 14% to $2.57. The crucial line was the Aetna insurance segment, the source of the prior two years of pain: its medical benefit ratio improved to 84.6% from 87.3%, beating the 86.3% analysts expected, and segment adjusted operating income rose nearly 53%. Medical-cost control is exactly what the bears doubted CVS could regain, and the company demonstrated it while cutting roughly $2 billion in costs, closing underperforming stores, and tightening its Medicare Advantage book. Management raised full-year adjusted EPS guidance to $7.30 to $7.50 and total revenue to at least $405 billion.

The valuation gives the turnaround a wide runway. At a forward P/E near 13.5x, CVS is discounted to the market and to its own history, and the inversion shows the price sits below what even a 5%-a-year decline in operating profit would warrant, computed on through-the-cycle margins. In other words, the market is pricing CVS as a melting business, and the Q1 results argue the opposite. The dividend yields around 3.5% and is comfortably covered by free cash flow of roughly $6 per share, and management is paying down the acquisition debt. Analysts have responded, raising targets into the $106 to $110 range with reduced perceived risk around PBM reform. The bull case is a deeply discounted, defensive integrated-healthcare leader executing a credible turnaround, where a normalizing Aetna and steady deleveraging close the gap to fair value.

Bear Case

The variable with the most leverage on this thesis is regulation, specifically pharmacy-benefit-manager reform, and the current price does not fully reflect how much of CVS's profit sits in the crosshairs. The filing describes how the Caremark PBM offers plan sponsors pricing that includes a retail-network differential or spread, the difference between the drug price the PBM charges the plan sponsor and what it pays the pharmacy (FY2025 10-K, accession 0000064803-26-000010). That spread is a meaningful profit source, and it is precisely what reform efforts target. The 2026 legislative session is debating a PBM Transparency Act that could mandate further disclosures and pressure the spread model, and any move toward pass-through pricing or banning spread would hit a high-margin slice of the most profitable part of the company. A single legislative change can reprice the PBM earnings stream, and the market has cycled through this fear before.

The other external pressures compound the regulatory risk. The Health Care Benefits segment serves Medicare Advantage, Medicare Supplement, prescription drug plans, and Medicaid members (FY2025 10-K, accession 0000064803-26-000010), all of which are government programs subject to reimbursement rate decisions, utilization trends, and policy shifts outside the company's control. Medicare Advantage reimbursement headwinds and rising medical utilization were the source of the 2024-2025 earnings collapse, and a single bad rate cycle or a return of elevated medical costs would reverse the MLR improvement that anchors the bull case. Retail pharmacy reimbursement is also under persistent pressure as drug-pricing economics tighten.

The debt magnifies all of it. Net debt of about $54 billion, roughly 2.3x operating income, is the legacy of the Aetna, Oak Street, and Signify acquisitions, and it leaves less cushion if a regulatory or medical-cost shock hits earnings. Interest coverage of 7.7x is adequate today but assumes earnings hold. The valuation X-ray underlines the fragility of the earnings base: the earnings-power family flags the stock as extremely rich relative to current normalized earnings, with only the growth-DCF reaching the price, because the operating margin is razor-thin at 1.5% and small changes in medical costs or PBM spread swing it sharply. The bear case is that CVS is a heavily indebted, thin-margin business whose profit pools are exposed to regulation and government reimbursement, where one adverse policy or medical-cost cycle could undo the turnaround the price is just beginning to credit.

Valuation

Invert the price first, noting that trailing earnings are depressed by the cycle, so the solve uses CVS's through-the-cycle margins rather than the trough. On that basis, at about 9x normalized operating income, the price sits below what even a 5%-a-year decline in operating profit would warrant, computed at a 7% cost of capital. That is a bound, not a solved point: the market is pricing CVS as if its profits will shrink, which is the read of a deep-value or distressed name, not a growing one. For a company that just raised guidance and posted double-digit adjusted EPS growth, that is a striking disconnect.

The valuation families split sharply. The earnings-power family flags the stock as extremely rich on current normalized earnings, a quirk of the 1.5% operating margin, where capitalizing a thin trailing profit produces a low fair value. The thin margin makes the earnings-power method an unreliable lens here; the more relevant frames, peer multiples and the discounted forward cash flows of a recovering Aetna and a steady PBM, support the price and then some.

The synthesis is that CVS is priced for stagnation or decline, and the question is whether the turnaround converts that into a re-rating. At a forward P/E near 13.5x, well below the market, the stock is discounted on the assumption that PBM reform, Medicare Advantage headwinds, and the debt load cap its earnings. If the Aetna MLR improvement holds and deleveraging continues, the normalized earnings power justifies a higher multiple and the analyst targets near $102 to $110 are the relevant anchors. If regulation or medical costs bite, the market's cautious pricing is the accurate read. This is a value-and-turnaround name where the price already embeds pessimism, so the asymmetry favors the recovery if execution holds.

Catalysts

The defining recent event was Q1 2026 results reported May 6, 2026: revenue exceeding $100 billion, up over 6%, adjusted operating income up over 12%, and adjusted EPS of $2.57, up over 14%. The standout was the Aetna insurance segment, where the medical benefit ratio improved to 84.6% from 87.3%, beating the 86.3% expected, and adjusted operating income rose nearly 53%. Management raised full-year 2026 adjusted EPS guidance to $7.30 to $7.50 and total revenue to at least $405 billion, and the stock rose about 7% on the print. The trajectory of the medical benefit ratio and progress on the Medicare Advantage margin goals, which management targets by 2028, are the operating signals that matter most to the turnaround thesis.

The dominant external catalyst is regulation. The 2026 legislative session is debating a PBM Transparency Act that could pressure the spread-pricing model at the heart of Caremark's profitability, so any legislative development is a direct catalyst in either direction; notably, several analysts have cited reduced perceived PBM-reform risk as a reason for recent target increases. Two other items are worth tracking: continued debt paydown against the roughly $54 billion net-debt load from prior acquisitions, and the expansion of clinical and GLP-1 programs that BofA cited in raising its target. The dividend yields around 3.5% and is well covered by free cash flow. Analyst sentiment is firmly positive, a Buy consensus with no holds or sells across the reporting analysts and targets ranging from about $70 to $115, with several houses recently raising into the $106 to $110 range. The next earnings report, the path of PBM reform legislation, and the durability of the Aetna margin recovery are the events most likely to move the thesis.

Sources: CVS Health Q1 2026 earnings (CNBC), CVS raises full-year 2026 guidance (PR Newswire), CVS hikes outlook as Aetna profit rises (Healthcare Dive), CVS regulatory pressure tests PBM margins (Simply Wall St).

Peer Cohorts (Per Segment, With Filing Citations)

Health Care Benefits (reported)

Health Services (reported)

Pharmacy & Consumer Wellness (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive CVS report on boothcheck